Astellas bid for CV Therapeutics turned hostile this morning when the Japanese drug firm offered $1 billion dollars for the company directly to shareholders.
The CVT board rejected Astellas’s second proposal last Friday stating that the Astellas proposal undervalued the company and is not in the best interest of the shareholders.
In a press release issued this [...]
PharmExec Blog
Follow Us
RSS
Bookstore
Astellas Keeps After CV Therapeutics